All In Biotech

Drug Trial Radar · NCT01722331

A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)

A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)

Last checked: Nov 20, 2026Latest source record: Mar 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 772 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

772

Actual

Start

Dec 6, 2012

Primary completion

Oct 28, 2015

Study completion Nov 10, 2021

Sponsor

Sponsor type
Industry
First posted
Nov 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.

Conditions

  • Plaque Psoriasis

Interventions

  • Tildrakizumab 200 mgDrug

    Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)

  • Tildrakizumab 100 mgDrug

    Tildrakizumab 100 mg/mL PFS

  • Matching PlaceboDrug

    Matching placebo to tildrakizumab PFS

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study)Time frame: Week 12 (or end of trial if prior to Week 12)
  2. Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study)Time frame: Baseline and Week 12 (or end of trial if prior to Week 12)
  3. Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study)Time frame: Up to 12 weeks
  4. Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study)Time frame: Up to 12 weeks
  5. Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study)Time frame: Up to 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.